专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3279729B1 NEGATIVE RESIST COMPOSITION AND RESIST PATTERN FORMING PROCESS 有权
公开(公告)号：EP3279729B1
公开(公告)日：2018-11-28
申请号：EP17184446.7
申请日：2017-08-02
申请人： Shin-Etsu Chemical Co., Ltd.
发明人： MASUNAGA, Keiichi , WATANABE, Satoshi , KOTAKE, Masaaki , YAMADA, Kenji , OHASHI, Masaki
IPC分类号： G03F7/004 , G03F7/039 , G03F7/20 , G03F7/038
CPC分类号： G03F7/0045 , C07C69/753 , C07C303/32 , C07C309/04 , C07C309/06 , C07C309/17 , C07C309/19 , C07C309/23 , C07C309/24 , C07C309/29 , C07C309/30 , C07C309/31 , C07C309/32 , C07C309/35 , C07C309/44 , C07C309/58 , C08F212/02 , C08F220/22 , C08F220/24 , C08F220/30 , C08F220/38 , C08F222/10 , C08F224/00 , C08F228/02 , C08F2220/283 , C08F2220/303 , C08F2220/382 , G03F7/0046 , G03F7/0382 , G03F7/162 , G03F7/168 , G03F7/2006 , G03F7/2037 , G03F7/322 , G03F7/38
摘要： A negative resist composition comprising (A) a sulfonium compound of betaine type and (B) a polymer is provided. The resist composition is effective for controlling acid diffusion during the exposure step, exhibits a very high resolution during pattern formation, and forms a pattern with minimal LER.

2. 发明公开

EP3176237A4 HYDROPHILIC OIL REPELLENT AGENT AND METHOD FOR MANUFACTURING SAME, AND SURFACE COVERING MATERIAL, COATING FILM, RESIN COMPOSITION, OIL-WATER SEPARATION FILTER MEDIUM, AND POROUS BODY 审中-公开
公开(公告)号：EP3176237A4
公开(公告)日：2018-02-07
申请号：EP15827639
申请日：2015-07-29
申请人： MITSUBISHI MAT CORPORATION , MITSUBISHI MAT ELECTRONIC CHEMICALS CO LTD
发明人： FUJITA MASATO , UOTANI MASAKAZU , KAMIYA TAKESHI , HONDA TSUNETOSHI , TAKANO DAISUKE
IPC分类号： C09K3/00 , B01D17/022 , C02F1/40 , C07C227/06 , C07C227/08 , C07C227/18 , C07C229/06 , C07C231/12 , C07C233/05 , C07C233/08 , C07C303/02 , C07C303/22 , C07C303/40 , C07C309/04 , C07C309/29 , C07C311/03 , C08K5/17 , C08L101/00 , C09D5/16 , C09D201/00
CPC分类号： C09D5/1625 , B01D17/02 , C02F1/40 , C07C227/06 , C07C227/08 , C07C227/16 , C07C227/18 , C07C229/06 , C07C229/12 , C07C231/02 , C07C231/12 , C07C233/05 , C07C233/08 , C07C303/02 , C07C303/22 , C07C303/38 , C07C303/40 , C07C309/04 , C07C309/13 , C07C309/29 , C07C311/03 , C07C311/05 , C07D207/10 , C07D211/38 , C07D241/04 , C07D265/30 , C08K5/17 , C08L101/00 , C09D5/16 , C09D7/001 , C09D7/20 , C09D7/40 , C09D201/00 , C09K3/00 , Y02W10/37
摘要： The hydrophilic oil repellent includes one or more types of nitrogen-containing fluorine-based compounds. The nitrogen-containing fluorine-based compound includes any one hydrophilicity imparting group selected from the group consisting of anion type hydrophilicity imparting groups, cation type hydrophilicity imparting groups, and amphoteric type hydrophilicity imparting groups in the molecule.

3. 发明授权

EP2851363B1 AGOMELATINE ACID RADICAL COMPOSITE, AND PREPARATION METHOD AND APPLICATION THEREOF 有权
标题翻译： AGOMELATINE酸自由基复合物及其制备方法和应用
公开(公告)号：EP2851363B1
公开(公告)日：2018-01-03
申请号：EP13790987.5
申请日：2013-05-14
申请人： Shanghai Righthand Pharmtech. Co., Ltd.
发明人： WANG, Haiping , CHI, Cheng , CHI, Zhengming , WANG, Jin , XU, Guanyu
IPC分类号： C07C309/30 , C07C309/29 , C07C303/32 , A61K31/185 , A61K31/165 , A61P9/00 , A61P25/22 , A61P25/18 , A61P25/24
CPC分类号： C07C233/18 , C07B2200/13 , C07C303/02 , C07C309/04 , C07C309/29 , C07C309/30
摘要： The present invention relates to an Agomelatine acid radical complex in formula (I) and the preparation method thereof (HX = H 2 SO 4 , RSO 3 H (R = CH 3 , Ph, 4-CH 3 Ph)). The solubility of the Agomelatine acid radical complex obtained by the method of the present invention is significantly improved compared with Agomelatine, has good stability and higher purity, and is suitable for application in finished-product medicinal preparations. The preparation process is quite simple, and a product with high purity can be obtained without special operations. (HX = H 2 SO 4 , RSO 3 H(R= CH 3 , Ph or 4-CH 3 Ph)).

4. 发明公开

EP3103793A4 LITHIUM STYRENE SULFONATE 有权
标题翻译： LITHIUMSTYROLSULFONAT
公开(公告)号：EP3103793A4
公开(公告)日：2017-06-28
申请号：EP15745753
申请日：2015-02-04
申请人： TOSOH CORP
发明人： SHIRAISHI CHIKARA , KASAHARA SENSHI
IPC分类号： C07C303/32 , C07C309/29
CPC分类号： C07C309/29 , C07B2200/13 , C07C303/32
摘要： To provide a novel lithium styrene sulfonate which is capable of solving a problem of an increase of the production cost due to drying under atmospheric pressure or reduced pressure at a temperature of at least 40°C and a problem of polymerization of lithium styrene sulfonate. The lithium styrene sulfonate is characterized in that when measured by using a Thermogravimetric-Differential Thermal Analyzer under measuring condition of heating at a temperature raising rate of 2°C/min in a nitrogen stream, the temperature at the top of the main endothermic peak in a range of from 80 to 170°C, is at least 120°C.
摘要翻译：本发明提供一种新型的苯乙烯磺酸锂，其能够解决由于在大气压下或在至少40℃的温度下减压干燥而导致生产成本增加的问题以及苯乙烯磺酸锂的聚合问题。苯乙烯磺酸锂的特征在于，在氮气流中以2℃/分钟的升温速度加热的测定条件下，使用热重 - 差热分析装置进行测定时，主吸热峰的顶部的温度为在80至170℃的范围内，至少为120℃。

5. 发明公开

EP3059227A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND SALT OR CRYSTAL THEREOF, PHARMACEUTICAL COMPOSITION, AND FLT3 INHIBITOR 有权转让
标题翻译：杂环化合物盐或晶体，其药物组合物和FLT3抑制剂含氮
公开(公告)号：EP3059227A1
公开(公告)日：2016-08-24
申请号：EP14854750.8
申请日：2014-10-15
申请人： Fujifilm Corporation
发明人： MIZUMOTO, Shinsuke , MATSUMOTO, Takuya
IPC分类号： C07D239/48 , A61K31/505 , A61P35/02 , A61P43/00
CPC分类号： C07D239/48 , A61K31/505 , C07B2200/13 , C07C55/10 , C07C57/15 , C07C65/11 , C07C309/29 , C07D239/42
摘要： An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or solubility, etc. and having superior FLT3 inhibitory activity. The present invention provides a salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)ammo)-4-(propylanmio)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide, or a crystal thereof. Since the salt or a crystal thereof has superior FLT3 inhibitory activity and shows superior physicochemical properties as drugs, such as storage stability, solubility, and so forth, it is useful for treatments of diseases or conditions relating to FLT3. The present invention also provides a pharmaceutical composition and FLT3 inhibitor containing the salt or a crystal thereof.
摘要翻译：本发明的一个目的是提供显示出优异的稳定性和/或溶解性等而具有优异FLT3抑制活性的化合物和药物组合物。本发明提供了（S，E）-N-（1的盐 - （（5-（2 - （（4-氰基苯基）氨基）-4-（propylanmio）嘧啶-5-基）戊-4-炔 -1-基）氨基）-1-氧代丙烷-2-基）-4-（二甲基氨基）-N-甲基丁-2-烯酰胺，或它们的结晶。由于盐或它们的晶体具有优异的FLT3抑制活性，并且显示出优异的物理化学性质如药物，：如储存稳定性，溶解度，等，它是有关FLT3的疾病或病症的治疗是有用的。因此，本发明提供药物组合物和FLT3抑制剂通过含有盐或它们的结晶。

6. 发明公开

EP2982675A4 SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF 有权
标题翻译：一种吡唑并喹啉衍生物的盐及其晶体
公开(公告)号：EP2982675A4
公开(公告)日：2016-08-10
申请号：EP14780139
申请日：2014-04-03
申请人： EISAI R&D MAN CO LTD
发明人： OZAKI SHUNSUKE
IPC分类号： C07D471/04 , A61K31/4745 , A61P25/28 , A61P43/00
CPC分类号： C07D471/04 , A61K31/4745 , C07B2200/13 , C07C57/145 , C07C309/29

7. 发明授权

EP2455368B1 2-[[[2-[(HYDROXYACETYL)AMINO]-4-PYRIDINYL]METHYL]THIO]-N-[4-(TRIFLUOROMETHOXY)PHENYL]-3-PYRIDINECARBOXAMIDE BENZENE- SULFONATE, CRYSTALS OF SAME, POLYMORPHS THEREOF, AND PROCESSES FOR PRODUCTION THEREOF 有权
标题翻译： 2 - [[[2 - [（羟基乙酰基）氨基] -4-吡啶基]甲基]硫代] -N- [4-（三氟甲氧基）苯基] -3-吡啶甲酰胺苯磺酸盐，它们的晶体，多晶型物，及其方法
公开(公告)号：EP2455368B1
公开(公告)日：2015-09-16
申请号：EP10799928.6
申请日：2010-07-16
申请人： Santen Pharmaceutical Co., Ltd
发明人： NIWA, Masashi , DEGUCHI, Hiroshi
IPC分类号： C07D213/82 , A61K31/455 , A61P27/02 , A61P29/00 , A61P35/00
CPC分类号： C07D213/82 , A61K31/455 , C07B2200/13 , C07C303/32 , C07C309/29 , C07D401/12
摘要： In the course of developing 2-[[[2 - [(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- N -[4 -(trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide(compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly. For solving these problems, we made examination focusing on the kind of the salt and, as a result, found that 1) benzenesulfonate of compound A does not decompose by light, humidity and other factors in a 1-week preliminary stability test (severe test), and has no problem in its storage stability, 2) a method of selectively producing two kinds of crystal forms of benzenesulfonate of compound A, and that 3) no mineral deposition in the stomach is observed even after a 4-week repeated oral administration.

8. 发明公开

EP2698371A4 NOVEL ANTI-PLATELET COMPOUND ADDITION SALT 有权
标题翻译：新复合盐除了血小板
公开(公告)号：EP2698371A4
公开(公告)日：2014-09-03
申请号：EP12771534
申请日：2012-04-09
申请人： GUANGZHOU HEERSHI PHARMA DEV CO LTD
发明人： YAN XIAOJING
IPC分类号： C07D495/04 , A61K31/4365 , A61P7/02
CPC分类号： C07D495/04 , C07C309/04 , C07C309/19 , C07C309/29 , C07C309/30

9. 发明公开

EP2723732A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF 有权转让
标题翻译： TRPV1-ANTAGONISTEN MIT DIHYDROXY-SUBSTITUENT UND IHRE VERWENDUNG
公开(公告)号：EP2723732A1
公开(公告)日：2014-04-30
申请号：EP12735333.2
申请日：2012-06-21
申请人： Purdue Pharma LP , Shionogi & Co., Ltd.
发明人： Shionogi&Co. Ltd. , TAFESSE, Laykea , ANDO, Shigeru , KUROSE, Noriyuki
IPC分类号： C07D417/12 , C07D417/14 , A61P29/00 , A61P1/04 , A61P13/00 , A61P25/02 , A61P25/04 , A61P19/02 , A61K31/428
CPC分类号： C07D417/14 , A61K31/428 , A61K31/496 , C07C57/15 , C07C59/255 , C07C309/29 , C07C309/30 , C07D417/12
摘要： The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R
1 , R
4 , R
8 , R
9 , and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI, an ulcer, IBD, and IBS, comprising administering to an animal in need thereof an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof.
摘要翻译：本公开涉及式（I）化合物及其药学上可接受的衍生物，其中R 1，R 4，R 8，R 9和m如本文所定义，包含有效量的式（I）化合物或其药学上可接受的衍生物以及用于治疗或预防与骨关节炎，骨关节炎，UI，溃疡，IBD和IBS相关的疼痛，疼痛，溃疡，IBD和IBS等症状的治疗或预防方法，其包括向有需要的动物施用有效量的式（I）化合物或其药学上可接受的衍生物。

10. 发明公开

EP2455368A4 2-[[[2-[(HYDROXYACETYL)AMINO]-4-PYRIDINYL]METHYL]THIO]-N-[4-(TRIFLUOROMETHOXY)PHENYL]-3-PYRIDINECARBOXAMIDE BENZENE- SULFONATE, CRYSTALS OF SAME, POLYMORPHS THEREOF, AND PROCESSES FOR PRODUCTION THEREOF 有权
标题翻译： 2 - [[[2 - [（羟基乙酰基）氨基] -4-吡啶基]甲基]硫代] -N- [4-（三氟甲氧基）苯基] -3-吡啶甲酰胺苯磺酸盐，它们的晶体，多晶型物，及其方法
公开(公告)号：EP2455368A4
公开(公告)日：2013-01-09
申请号：EP10799928
申请日：2010-07-16
申请人： SANTEN PHARMA CO LTD
发明人： NIWA MASASHI , DEGUCHI HIROSHI
IPC分类号： C07D213/82 , A61K31/455 , A61P27/02 , A61P29/00 , A61P35/00
CPC分类号： C07D213/82 , A61K31/455 , C07B2200/13 , C07C303/32 , C07C309/29 , C07D401/12
摘要： In the course of developing 2-[[[2 - [(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- N -[4 -(trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide(compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly. For solving these problems, we made examination focusing on the kind of the salt and, as a result, found that 1) benzenesulfonate of compound A does not decompose by light, humidity and other factors in a 1-week preliminary stability test (severe test), and has no problem in its storage stability, 2) a method of selectively producing two kinds of crystal forms of benzenesulfonate of compound A, and that 3) no mineral deposition in the stomach is observed even after a 4-week repeated oral administration.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式